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Abstract 
Human adenoviruses (HAdVs) infect respiratory, gastrointestinal and urinary tracts, 
and give rise to eye infections and epidemic keratoconjunctivitis (EKC). They persist 
in lymphoid tissue, and cause morbidity and mortality in immunocompromised 
people. Treatments with significant post-exposure efficacy are not available. Here, 
we report that inhibition of the cell cycle-dependent kinase 9 (Cdk9) by RNA-
interference, or the compound Flavopiridol blocked infections with HAdV-C2/5, EKC-
causing HAdV-D8/37, and progeny formation in human corneal epithelial and cancer 
cells. Flavopiridol abrogated the production of the immediate early viral trans-
activating protein E1A without affecting nuclear import of viral DNA. In morphometric 
plaque assays, the compound exhibited anti-viral efficacy in both pre- and post-
exposure regimens with therapeutic indexes exceeding 10. The study identifies Cdk9 
as a post-exposure drug target against adenovirus infections in vitro, and suggests 
that the clinically tested anti-cancer drug Flavopiridol is a candidate for treating 
adenoviral EKC, or adenovirus emergence upon immune suppression.  
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Introduction 
Viral disease by recurrent or chronic agents, such as influenza virus, hepatitis 
viruses or HIV, or emerging agents, such as Ebola, Hanta or Zikavirus has had a 
long history and a strong impact on human evolution 1 2. This involves infections 
between humans, or between humans and animals in zoonotic and anthroponotic 
transmissions. Viral disease is difficult to combat because viruses subvert host 
defense, are genetically diverse, occur in large numbers, and readily evolve in 
response to environmental pressure.  
Adenoviruses (AdVs) have evolved from bacteriophages. Today’s adenoviruses are 
genetically distinct from bacteriophages, and infect most vertebrates. They are non-
enveloped icosahedral particles with protruding fibers for cell attachment, and a 
pressurized DNA-protein core for stepwise uncoating, in response to cellular cues 3, 
4. More than 70 different human AdV (HAdV) serotypes and more than 70 additional 
human adenovirus genomes are known, and classified into 7 species (A-G) (see 
https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?p=7&id=10508). 
HAdVs replicate in the host nucleus and spread by lytic infection 5. They cause a 
number of diseases, including respiratory and gastrointestinal disorders, as well as 
epidemic keratoconjunctivitis (EKC) 6. Most diseases caused by AdV are self-
limiting, due to strong innate and adaptive immunity, which provides protection 
against related serotypes 6-8. In immunocompromised individuals, however, HAdV-
species C (HAdV-C2/5) cause severe morbidity and mortality. Post-exposure 
adenovirus disease correlates with virus persistence and ongoing virus production in 
T-lymphocytes and primary human bronchial epithelial cells 7, 9.  
Besides uncontrolled proliferation in immunocompromised individuals, adenoviral 
disease has additional unmet medical needs, such as EKC, which threatens eye 
vision, and causes large economic losses. Although antiviral agents, such as 
cidofovir and ribavirin have been used in oral or topical applications against HAdV, 
clinical success was limited due to narrow efficacy and toxicity 10. Notably, ribavirin is 
inactive against HAdV-D8/19/37, the main agents causing EKC, and there are 
additional non-tested EKC-associated adenoviruses, including types 53, 54 and 56. 
Clinically approved anti-adenoviral drugs with significant post-exposure efficacy are 
not available. 
Here, we provide in vitro evidence for post exposure efficacy of two clinically tested 
cell cycle dependent kinase (Cdk) inhibitors against EKC-causing HAdV types. 
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Flavopiridol (FLV) also known as Alvocidib, has previously been tested in phase-IIB 
clinical trials against leukemia. FLV is a semi-synthetic flavonoid compound inhibiting 
the cell cycle-dependent kinase Cdk9 with Ki of 3nM, and other Cdks, such as Cdk1, 
Cdk2, Cdk4, Cdk6, Cdk7 with Ki of 10nM-100nM 11. It suppresses the replication of 
herpes simplex virus (HSV), human cytomegalovirus (HCMV) and human immune 
deficiency virus (HIV) 12. FLV is clinically active against acute myeloid leukemia in 
combination therapy 13, 14. CYC202 is a substituted purine analog, and inhibits Cdk2, 
Cdk7 and Cdk9. It is used to treat non-small cell lung cancer (NSCLC), Cushing's 
disease, leukemia, HIV and HSV infections, as well as chronic inflammation 
disorders 15. Cdk9 controls transcriptional elongation. It forms a complex with cyclin 
T1, T2 or K, the so called positive transcription elongation factor beta P-TEFb, for a 
comprehensive review, see 11. P-TEFb coordinates elongation after Pol II has been 
halted by DSIF (5,6-dichlorobenzimidazole 1-β-d-ribofuranoside‐sensitivity‐inducing 
factor) and NELF (negative elongation factor). P-TEFb phosphorylates DSIF and 
NELF, as well as the carboxy‐terminal domain (CTD) of Pol II. This relieves 
repression, recruits the elongation complex, splicing and 3′-polyadenylation 
machineries, and enables transcription elongation.  
Cdk9 enhances E1A transcription and HAdV-C5 infection through facilitating the 
recruitment of the Pol II mediator complex by the large E1A protein 16. It has been 
suggested as an anti-viral target based on the notion that the broad Cdk9 inhibitor 
FIT-039, which inactivates other kinases, including Abl, IKKa, Rse and Rsk4 
inhibited adenovirus replication measured by qPCR in cell-culture 17. Here, we 
extend these data by showing that either FLV or the knock-down of Cdk9 inhibited 
the expression of the immediate early adenoviral protein E1A, and blocked the 
spreading of EKC-causing HAdV in post-exposure treatment, measured by live cell 
plaque assay and progeny titration.  
 
Results and Discussion 
Adenovirus infection is well known to drive the cells into S-phase, and thus enhance 
viral DNA replication 18. We conducted a mini-drug screen with chemicals, which 
inhibit cell cycle progression or check points, and thereby arrest cells in particular 
cell cycle phases, or allow them to ignore stop signals and continue proliferation. To 
assess combinatorial effects of drugs and infection on toxicity we used 
‘xCELLigence’ to measure cell impedance in real-time. xCELLigence provides label 
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free, real-time assessment of cell numbers, size, shape and substrate interaction, 
and a sensitive readout for cell toxicity 19. Among the drugs tested in the mini-screen, 
the clearest effect on impedance was seen with FLV, which strongly reduced HAdV-
C5 cell killing in a dose-dependent manner up to 125 nM (Fig. 1A, B). 
Representative impedance plots show cell indexes (CI) as a function of time, where 
FLV-treated cells infected with adenovirus showed a significant increase in CI 
compared to control infected cells (Fig. 1B). FLV inhibits a number of cell cycle 
dependent kinases, arrests cells in G1/S, and enhances apoptosis, for example upon 
genotoxic stress 11. FLV was more effective at blocking HAdV cell killing than BMS-
265246, a potent Cdk1/Cdk2 inhibitor arresting cells in G2 20, or AZD-7762, which 
blocks checkpoint kinases and overrides DNA damage-induced cell cycle arrest 21, 
or CHIR-124, which inhibits the G2-M checkpoint 22 (see Fig. 1A).  
Importantly, FLV inhibited HAdV-C5 infection, as shown by immunofluorescence 
staining of newly synthesized viral protein VI (Fig. 1C). FLV leads to a cell cycle 
arrest in G1/S by inhibition of cyclin D/Cdk4 and cyclin E/Cdk2 11, 14. We confirmed 
this notion with fluorescent ubiquitinated cell cycle indicator (FUCCI)-HeLa cells 
showing an enrichment of yellow G1/S cells upon FLV treatment at nanomolar 
concentrations for 24h (Fig. 1C). HeLa-FUCCI cells express green and red-
fluorescent proteins fused to geminin (monomeric Azami Green labeled Geminin, 
dubbed as mAG-hGem), and Cdt1 (monomeric Kusabira orange fused to Cdt1, 
dubbed as mKO-Cdt1), respectively 23. mAG-hGem undergoes proteasome-
dependent degradation in G1 yielding red G1 cells, whereas cells in S, G2, and M 
phases are green, since Cdt1-RFP is ubiquitinated and degraded in these cell cycle 
phases. Early S-phase cells express both Cdt1 and geminin and appear yellow / 
orange, and in early G1, no fluorescence marker is expressed. As expected, HAdV-
C5 infection enhanced the fraction of G1/S cells more than 2-fold to about 50%, 
compared to untreated, uninfected cells, which contained about 25% G1/S cells (Fig. 
1C). Notably, FLV only slightly reduced the proportion of G1/S cells and lead to a 
small enhancement of S/G2/M cells upon infection. We conclude that FLV strongly 
inhibits adenovirus infection, and cell cycle progression.  
Besides inhibiting the cell cycle, low nanomolar concentrations of FLV potently 
inactivate the positive transcription elongation factor beta (P-TEFb), and block most 
RNA Pol II (PolR2)-mediated transcription in vivo for a comprehensive review, see 
11. In human cells, the P-TEFb complex promotes elongation of the paused 
transcripts. It is composed of Cdk9 and cyclin T1, T2 or K depending on the cell type. 
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Elongation of early adenovirus transcripts has been shown to be dependent on Cdk9 
recruitment to virus promoters 16. We confirmed the importance of Cdk9 for HAdV 
infection by RNAi of Cdk9 which strongly reduced protein VI expression, in good 
correlation with Cdk9 knockdown (Fig. 1D). We found that adenovirus-infected HeLa 
cells increased the levels of PolR2A by a factor of about 11, as indicated by Western 
blots normalized to a-tubulin (Fig. 1E). Adenovirus-infected human diploid fibroblasts 
(HDF), which were immortalized with telomerase reverse transcriptase (TERT) 
likewise increased the PolR2A levels 1.9-fold compared to uninfected cells 24h pi 
(see later in Fig. 3C). This increase in PolR2A is in good agreement with earlier 
SILAC proteomics analyses, which found a 1.65 fold increase of PolR2A compared 
to control cells normalized to a-tubulin at 24h pi 24. The C-terminal repeat domain 
(CTD) of PolR2A is a flexible scaffold for recruiting a variety of factors controlling 
RNA processing, and transcription elongation, including P-TEFb 25. In agreement 
with the important role of Cdk9 in regulation of adenovirus transcription 17, FLV 
treatment at 125 nM completely blunted the induction of PolR2A by adenovirus, 
while not affecting the PolR2A levels of uninfected cells (Fig. 1E, and Fig. 3C). This 
suggests that FLV represses transcription in adenovirus-infected cells, in agreement 
with affecting the function of its target Cdk9 in transcription. In summary, FLV targets 
Cdk9, inhibits adenovirus infection, and maintains a large fraction of the infected 
cells in G1/S.  
The first gene transcribed from the incoming viral genome is E1A. E1A proteins are 
natively unfolded. They promiscuously bind to a large range of host proteins, and 
activate viral and host gene transcription 18. E1A transcription is subject to interferon-
mediated repression, which can lead to persistent infections and repress lytic 
replication 9. FLV at 63, 125 or 250 nM strongly suppressed E1A expression at 5h pi 
in HeLa-ATCC cells (Fig. 2A). E1A inhibition at 16h pi was much weaker than at 5h 
pi, when 63 nM or 125 nM of FLV was used. These results showed that despite 
continuous presence, FLV transiently inhibited the production of the immediate early 
viral gene product E1A, possibly by lowering the concentration of active P-TEFb. In 
contrast, essentially no E1A was detected up to 16h pi at 250 nM FLV.  
We next tested if nuclear import of the incoming viral DNA (vDNA) was affected by 
FLV. Nuclear import of vDNA is a prerequisite for viral immediate early gene 
expression 18, 26. Cells were infected with EdC-labeled HAdV-C5 with and without 
FLV, fixed 3.5h pi and immunostained for capsid protein hexon, and vDNA using 
click-chemistry, as described 26. In all conditions viral capsids were found to be 
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associated with the infected cells (Fig. 2B). Quantification of the vDNA puncta over 
nuclei and within the cell boundaries showed that at average about 80% of the 
incoming capsid-free, uncoated vDNA localized to the nuclear area, without 
significant differences between control and FLV-treated cells (Fig. 2B). As expected 
there was large cell-to-cell variability, and some cells imported below 50% of the 
incoming vDNA. This indicates that FLV does not affect virus entry and nuclear 
import of vDNA at 3.5h pi. 
We next tested the efficiency of FLV in blocking adenovirus infection post-exposure. 
HeLa-ATCC cells were infected with replication-competent HAdV-C2-dE3b_GFP for 
24h. This virus enables the visualization of cell lysis and subsequent plaque 
formation by high-throughput microscopy 5. FLV was then added for 24h, cells fixed, 
imaged by high-throughput microscopy and comets of infected cells quantified using 
Plaque 2.0 software 27. Comets are amorphous plaques arising by virus spreading 
from a donor cell to neighboring cells in convection currents through the medium 5. 
As shown in Fig. 2C, FLV slightly inhibited the formation of viral plaques at 63 nM, 
and completely abrogated plaque formation at 125 or 250 nM. This demonstrates 
that FLV is a potent adenovirus infection inhibitor with post-exposure efficacy. This 
conclusion was strengthened by the observation that the virus titers were equally 
reduced when FLV was added before virus entry or immediately post vDNA import 
into the nucleus at 4h pi (Fig. 2D). Similar results were obtained with human diploid 
fibroblasts immortalized with telomerase reverse transcriptase (HDF-TERT), or 
normal human fibroblasts WI38, which strongly attenuated adenovirus infection upon 
FLV treatment before or after virus entry (Fig. 3A, B, D). Infection inhibition of HDF-
TERT was compatible with a block in viral transcription as suggested by the 
observation that FLV blunted PolR2A induction by adenovirus (Fig. 3C). We 
conclude that FLV inhibits adenovirus infection of HeLa and normal human 
fibroblasts after nuclear import of the viral genome.  
So far, we have shown that the Cdk inhibitor FLV or the knock-down of Cdk9 inhibit 
infection of cancer cells and normal human fibroblasts with adenoviruses of the 
species C by inhibiting the production of E1A. We next tested the susceptibility of 
HAdV-C2-dE3b_GFP and epidemic keratoconjunctivitis (EKC)-causing species D 
adenoviruses to Cdk inhibitors in human corneal epithelial cells (HCE). FLV and 
Dinaciclib strongly target Cdk9, and have clinical activity in patients with chronic 
lymphocytic leukemia, and FLV appears to have a more narrow therapeutic index for 
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ovarian cancers in patients than Dinaciclib 14. In addition to FLV, we tested CYC202, 
which has phase-IIB clinical data from lung and breast cancer clinical settings. 
CYC202 is a potent inhibitor of Cdk2/cyclin E, Cdk7/cyclin H, and Cdk5/p35 with 
submicromolar IC50 values. At higher micromolar concentrations, it leads to 
reduction of transcription, possibly via inhibition of Cdk7 and Cdk9 complexes. As a 
control, we included the PolR2 inhibitor DRB (5,6‐dichlorobenzimidazole 1-β‐d‐
ribofuranoside), which inhibits the initiation of RNA synthesis 28. HCE cells were 
protected from infection with HAdV-C2-dE3b_GFP in presence of nanomolar 
concentrations of FLV, or micromolar concentrations of CYC202 or DRB (Fig. 4A, B). 
Likewise, infection of HCE cells with HAdV-D8 was strongly inhibited, indicated by 
immuno-staining of viral hexon and protein IIIa (Fig. 4C). Similar results were 
obtained with HAdV-D37 and HAdV-C2_dE3B_GFP (see Fig. 4D, and data not 
shown). We noticed a slight decrease in cell number upon FLV, CYC or DRB 
treatments for 24h. In case of FLV, this was due to cell cycle inhibition rather than 
toxicity as indicated by xCELLigence impedance measurements (Fig. 1C and Fig. 
4D, F).  
Dose-response curves for anti-viral efficacy and toxicity indicated therapeutic 
indexes (TI = LD50/IC50) of >10 for FLV in case of HAdV-D8/37 and C2, and TI 
between 3.6 and 10 for CYC202 and DRB (Fig. 4D). LC50 denotes the drug 
concentration with 50% cell lethality. Determination of virus titers produced at IC50 
and IC90 concentrations of the inhibitors 48h pi showed very strong efficacy of FLV at 
60 nM against HAdV-D8/37 and C2, and micromolar efficacy of CYC202 and DRB 
(Fig. 4E). Finally, to assess the dynamic drug-induced toxicity in HCE cells, we 
analyzed time-dependent LC50 for these inhibitors using xCELLigence. The results 
indicated that FLV, CYC202 and DRB were well tolerated with stable LC50 values 
even after 6 days of drug incubation (Fig. 4F). We conclude that the drugs unlikely 
inhibit adenovirus infection by general cell toxicity. 
We had previously screened for factors enhancing adenovirus-induced cytotoxicity, 
and found that RNA silencing of Arf1 GTP exchange factor GBF1, or its chemical 
inhibition with Golgicide A (GCA) enhances adenovirus infection and killing 29. The 
possibility of combining cytotoxicity triggered by cell cycle inhibition together with 
adenovirus infection prompted us to perform a small screen with cell cycle inhibitors, 
AZD-7762, BMS-265246, CHIR-124 and FLV. Instead of infection-enhancing effects, 
we found that cell cycle inhibitors impaired adenovirus infection in cell cultures, 
including infection of human cornea epithelial cells with EKC-causing adenovirus 
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types. Our study suggests that the transcription elongation factor Cdk9 is key for 
expression of the immediate early adenoviral protein E1A. E1A gene expression is 
indispensible for virus growth, and it also antagonizes interferon signaling and 
controls cell cycle progression 8, 9, 18. E1A is regulated by an upstream enhancer 
region and a number of transcription factors, and signaling 3, 30. In addition, the large 
E1A protein together with the mediator complex (MED) 26 and the elongation 
catalyst Cdk9 are important for E1A transcription 16. Cdk9 is inhibited by nanomolar 
concentrations of FLV, and micromolar concentrations of CYC202 14. These 
conditions match the inhibitory profiles against adenovirus infections described here.  
FLV has a unique mode of action by targeting Cdk9 of the P-TEFb complex and 
thereby inhibiting transcriptional elongation. FLV is particularly active in tumor cells 
that are sensitive to apoptosis inducers, such as chronic lymphocytic leukemia (CLL) 
and mantle cell lymphoma 14. This is likely due to the fact that chronic lymphocyte 
leukemia cell survival is strongly dependent on anti-apoptotic proteins XIAP and Mcl-
1, which are encoded by short-lived transcripts 31. FLV reduces the abundance of 
short-lived unstable mRNAs. Notably, the adenoviral E1A transcripts are short-lived 
with a half-live of about 45 min 32. The long E1A proteins are also short lived with a 
half live of a few hours 33. We thus anticipate that E1A transcripts are subject to 
reduction by FLV. In fact, FLV inhibition of transcription is transient, for example, 
about 70% of the genes had reduced expression upon 300 nM FLV treatment within 
a few hours, although some genes showed enhanced expression, and cells recover 
from FLV treatment after about one day 11. Such transient inhibition is sufficient to 
delay the production of E1A proteins (see Fig. 2). We speculate that Cdk9 in the P-
TEFb complex cooperates with MED to enhance PolR2-mediated transcription and 
elongation of E1A mRNA. This coincides with our observation that PolR2 levels are 
enhanced in adenovirus infection, and suppressed by FLV. This scenario is in 
agreement with earlier proteomics data suggesting that E1A 13S is linked to MED23 
16. Transcriptional activation of E1A through Cdk9 may enforce a positive feedback 
loop, and account for a strong enhancement of E1A expression early in adenovirus 
infection.  
Our results also go along with the notion that transcription is controlled by factors 
negatively regulating elongation, such as DSIF and NELF, which are subject to 
inhibition by Cdk9 activity. Notably, DRB and FLV inhibit P-TEFb and mRNA 
production through impairment of transcription elongation 34. This implies that Pol II 
is paused at promoter proximal sites, ready to receive activation signals (reviewed in 
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11). Projected to adenovirus, this may allow for rapid and synchronous activation of 
viral genomes in the nucleus, and help to overcome innate anti-viral networks. 
The data here have implications for treating EKC-causing adenoviruses, and 
emerging adenoviruses upon immune-suppression. Viral EKC involves human 
adenoviruses of the species D 6, in particular the FLV-sensitive HAdV-D8, D19 and 
D37. FLV also inhibits HAdV-C5, which persistently infects human lymphoid cells, 
including T lymphocytes in tonsil and adenoid tissues, and rises to high titers in 
immunocompromised individuals 35. The data here suggest that FLV and other Cdk9 
inhibitors are potent candidates for development of topically applicable anti-
adenoviral drugs against EKC. FLV can potentially be developed for treatment of 
viral emergence upon immune suppression owing to its rather broad anti-viral 
spectrum. 
 
Methods 
HCE cells immortalized with a recombinant SV40-adenovirus vector were kindly 
obtained from Dr. Karl Matter (University College London) 36. HeLa-FUCCI cells 
kindly provided by Dr. Cornel Fraefel (University of Zurich) were grown on 96-well 
imaging plates (Greiner Biosciences), infected with HAdV-C5_wt at multiplicity-of-
infection (moi) 1 in the presence of FLV (63 and 125 nM) and fixed with 
paraformaldehyde 18h pi. Nuclei were visualized with DAPI, and protein VI 
expression was used to estimate the infection efficiency 37. Nuclear stain of DAPI 
was used to segment cells in different cell cycle stages using Cell Profiler Analyst 
software and Machine Learning Algorithms 5, 27, 29, 38. HeLa-FUCCI cells express 
mKO-Cdt1 (orange, G1 phase), and mAG-hGem (green, S/G2/M phase). A small 
gap in fluorescence change from red to green indicates a G1/S transition 23. The 
customized software differentiated between G1, G1/S and S/G2/M cells. Procedures 
describing viruses, cells, transfections, xCELLigence, click chemistry for viral DNA 
detection have been described before 26, 29, 37, 39.  
Detailed methods are described in the Supporting Information file: 1) Cell lines and 
viruses. 2) Transfection, drug inhibition, infection. 3) xCELLigence. 4) Western 
blotting. 5) Scoring of cells in different cell cycle phases using Machine Learning. 6) 
Click chemistry and visualization of single viral DNA dots. 6) Virus growth assay. 7) 
Supporting references. 
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Figure Legends 
Fig. 1: Knock-down or chemical inhibition of Cdk9 inhibits HAdV 
infection 
(A) Effects of cell-cycle inhibitors on adenovirus-induced cytotoxicity measured with 
xCELLigence. CIT50 is the time-point when the impedance readout (Cell Index, CI) 
reaches 50% of maximum impedance of control (DMSO) cells. ∆CIT50 is the 
difference between CIT50 of drug-treated and control cells. The higher the ∆CIT50 
values are, the stronger is the inhibition of infection. The plot shows a linear 
correlation of ∆CIT50 and FLV dose up to 125 nM. Note that the effects of BMS 
(Bristol-Myer Squib)-265246, AZD (AstraZeneca)-7762 and CHIR (Chirion)-124, 
which primarily affect the cell cycle, have small effects on increasing the ∆CIT50 
values.  
(B) Representative CI profiles for FLV inhibition of adenovirus infection determined 
by xCELLigence. Drug was added together with the virus. The horizontal dashed line 
indicates CI50 of control cells.  
(C) Cell cycle analyses in presence of FLV and HAdV. HeLa-FUCCI cells were 
incubated with FLV in presence or absence of HAdV-C5-wt (moi 1) for 24h, fixed and 
analyzed for infection by anti-protein VI immuno-staining. The zoomed-in regions 
indicate cells in G1 (red), G1/S (yellow) and S/G2/M (green) phases of cell-cycle. 
Quantification of cells in different cell-cycle phases was performed using Cell 
Profiler. These results imply that the G1/S cell cycle inhibitor FLV does not affect the 
cell cycle control exerted by adenovirus. 
(D) HeLa-ATCC cells were transfected with siRNA against Cdk9 or scrambled (NT) 
for 48h as described 40, infected with HAdV-C2-dE3b_GFP for 18h, fixed and probed 
for infection using anti-protein VI antibody. Mean and SEM values are shown from 
two technical replicates of a representative experiment and the experiment was 
repeated two times. Levels of Cdk9 were determined by Western blotting using beta-
tubulin as loading control.  
(E) Total RNAP2A levels are enhanced in adenovirus-infected HeLa-ATCC cells. 
Cells were infected with HAdV-C2-dE3b_GFP in the presence of FLV for 24h, lysed 
and analyzed by Western blotting for RNAP2A levels using an antibody against the 
CTD (Abcam ab817). PolR2A levels relative to alpha-tubulin are indicated, including 
SEM from two independent experiments. 
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Fig. 2: Flavopiridol inhibits early viral gene expression but not nuclear 
genome import 
(A) FLV delays the production of E1A proteins in adenovirus infected HeLa-ATCC 
cells. Cells were infected with HAdV-C5 in presence or absence of FLV and E1A 
levels were determined by Western blots at 5 and 16h pi using beta-tubulin as 
loading control. One of three representative experiments is shown.  
(B) No effect of FLV on virus association with cells and nuclear import of vDNA. 
HeLa-ATCC cells were incubated with EdC-labeled HAdV-C5, fixed 3.5h pi and 
probed for viral-DNA by copper-catalyzed click chemistry. Viral capsids were stained 
with anti-hexon antibody and imaged with a Leica SP8 upright confocal microscope. 
Distribution of single viral genomes in nuclei and cytoplasm was assessed by 
segmenting the maximal projections of images using Cell Profiler. Nuclear capsid-
free vDNA dots normalized to the total vDNA are shown per cell.  
(C) FLV inhibits adenovirus infection post-exposure. A549 cells were incubated with 
HAdV-C2-dE3b_GFP (moi 0.0008) for 24h, followed by addition of FLV for 24h. 
Samples were fixed, DAPI-stained, imaged by high-throughput microscopy and 
analysed for viral plaques using Plaque 2.0. 
(D) Post-entry anti-viral efficacy of FLV. HeLa-ATCC cells were infected with HAdV-
C2-dE3b_GFP for 1h, washed, incubated with FLV, or without FLV for 3h, followed 
by FLV addition at 4h pi. At 48h pi, virus titers in the combined cell and supernatant 
fractions were determined on HeLa-ATCC cells using GFP as a readout 18h pi. The 
mean numbers of GFP-positive cells are shown including SEM from two replicates of 
a representative experiment, and the experiment was repeated two times. 
 
Fig. 3: Cdk-targeting agents inhibit EKC-causing adenoviruses in normal 
human cells 
(A) HDF-TERT cells were infected with HAdV-C2-dE3b_GFP in the presence of FLV, 
fixed at 24h pi, immuno-stained for viral E1A proteins, and analyzed using Cell 
Profiler. Mean and SEM values are shown from two replicates of a representative 
experiment and the experiment was repeated two times. 
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(B) Post-entry anti-viral efficacy of FLV in HDF-TERT cells. Cells were inoculated 
with viruses for 1h, followed by washing and addition of FLV 4h pi. At 72h pi, cell- 
and supernatant-associated viruses were titered on HeLa-ATCC cells using GFP as 
a readout 18h pi. The mean numbers of GFP positive cells are shown including SEM 
from two replicates of a representative experiment and the experiment was repeated 
two times. 
(C) Total RNAP2A levels are enhanced in adenovirus-infected HDF-TERT cells. 
Experiment was conducted as described in Fig. 1E. PolR2A levels relative to alpha-
tubulin are indicated, including SEM from two independent experiments. 
(D) FLV blocks adenovirus-induced cytopathic effects in WI38 cells. Cells were 
infected with HAdV-D37 in the presence of FLV (added 4h pi) and analyzed by 
differential interference contrast imaging 48h pi. 
 
Fig. 4: Cdk-targeting agents inhibit EKC-causing adenovirus in HCE cells 
(A, B) HCE cells were infected with HAdV-C2-dE3b_GFP in the presence of IC50 and 
IC90 amounts of FLV, CYC202 (CYC) and DRB, fixed at 24h pi, and immuno-stained 
for viral proteins E1A and protein VI. Mean and SEM values are shown from two 
replicates of a representative experiment and the experiment was repeated two 
times.  
(C) Immunofluorescence staining against hexon and protein IIIa shows inhibition of 
HCE infection with the EKC-causing adenovirus serotype HAdV-D8 in presence of 
nanomolar concentrations of FLV.  
(D) Infection inhibition and cell toxicity profiles of FLV, CYC202 and DRB. The 50% 
efficiency of infection inhibition (IC50) has been determined using anti-hexon 
immunofluorescence, and 50% cellular toxicity levels (CI50) were determined from CI 
measurements with xCELLigence. Relative cell viability is indicated as 1 – [(CIno drug – 
CIdrug)/CIno drug]. The table shows the therapeutic indexes (TI = CI50/IC50) of FLV, 
CYC202 and DRB for HAdV-C2, HAdV-D8 and HAdV-D37. 
(E) Estimation of viral titers at IC50 and IC90 values of FLV, CYC202 and DRB in 
HAdV-C2, D8 and D37 infected HCE cells. Cells were inoculated with viruses in the 
presence of indicated drugs, progeny particles collected at 48h pi, and titers of 
 15 
viruses determined on HeLa-ATCC cells by counting the anti-hexon positive cells 
18h pi. Mean and SEM values from two experiments are shown. 
(F) Real-time toxicity measurement of FLV, CYC202 and DRB in HCE cells for up to 
6 days post treatment. Cells were seeded on xCELLigence E-well plates, drugs 
added 56h post seeding, and CI measured at intervals of 15 min. CI50 values were 
estimated at each of these intervals, and plotted against time. Horizontal dotted lines 
indicate the average CI50 values over the entire period. Green and red lines indicate 
two time-points from FLV-treated cells at 80 and 130h post treatment, respectively. 
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Cell lines and viruses 
HeLa-ATCC and A549 (American Type Culture Collection, ATCC), human corneal 
epithelial (HCE) cells were obtained from Dr. Niklas Arnberg (UMEA University, 
Sweden) were grown at 37˚C in 5% CO2 environment in Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma) supplemented with 7.5% fetal calf serum (FCS; 
Life Technologies), as described 1. Replicating wild type HAdV-C5 (HAdV-C5_wt) 
and HAdV-C2-dE3b_GFP were grown in A549 cells as described before 2, 3. Major 
EKC-causing adenovirus serotypes D8 and D37 were plaque purified and amplified 
in A549 cells as described for HAdV-C2 4.  
 
Transfection, drug inhibition, infection  
Quantification of infections after drug treatment and siRNA transfections were 
performed in 96-well plate format. Small-interfering RNA (siRNA; ON-TARGET Plus 
SMARTPool; Dharmacon) transfection experiments and drug treatments were done 
exactly as described previously 5. All drug incubations were done at the time of 
addition of virus, and the cells were fixed at indicated time points pi. Antibodies 
used for immunofluorescence were against protein-VI 6, hexon (Mab8251 pan-
adeno, Abcam) and protein-IIIa 7. For post exposure experiments, FLV was added 
24h pi. 
 
xCELLigence  
xCelligence system (Roche Appliced Science and ACEA Biosciences) used for 
quantifying HAdV cytotoxicity was done exactly as described 5. For estimation of 
long-term toxicity effects of drugs, cells were grown on E-view plates for 48h, and 
serial dilutions of drugs were added. CI was recorded every 15 min and drug 
concentrations at which the CI dropped to 50% of untreated cells (CI50) was plotted 
for all time points. Using this pipeline, the long-term effect of drugs was monitored 
until 6 days post seeding. The average value was taken as a toxicity index for the 
different drugs. 
 
 S3 
Western blotting 
HeLa-ATCC cells were grown in 24-well plates and infected with HAdV-C5-wt 
multiplicity of infection (moi) 200 in the presence of FLV (63, 125 and 250 nM) at 
37˚C for 5 and 16h, and cell extracts were collected in lysis buffer (0.2 ml of 200 
mM Tris, pH 8.8, 20% glycerol, 5 mM EDTA, 50 mM DTT, 5% SDS, 0.02% 
bromophenol blue), boiled at 95˚C for 5 min and sheared through G21 needles 
(Sterican). Proteins were resolved on 15% polyacrylamide gels, transferred to a 
poly-vinylidene-difluoride membrane (Amersham) and blocked with 5% milk powder. 
Proteins were detected using anti-E1A M73 (Millipore 05-599), anti-PolR2A CTD 
(Abcam, ab817), anti-α-tubulin (Sigma T-9026) and ß-tubulin (Amersham). 
 
Scoring of cells in different cell cycle phases using Machine Learning 
HeLa-FUCCI cells kindly provided by Dr. Cornel Fraefel (University of Zurich) were 
grown on 96-well imaging plates (Greiner Biosciences), infected with HAdV-C5_wt 
(moi 1) in the presence of FLV (63 and 125 nM) and fixed with paraformaldehyde 
18h pi. Nuclei were visualized with DAPI, and protein VI expression was used to 
estimate the infection efficiency 6. Nuclear stain of DAPI was used to segment cells 
using Cell Profiler 2, 5, 8, 9. Quantification of cells in different cell cycle stages was 
performed using Cell Profiler Analyst software and Machine Learning Algorithms 10, 
11. FUCCI plasmid in HeLa cells expresses Kusabira orange fused Cdt1 gene 
(mKO-Cdt1) which indicates G1 stage, and Azami Green-labeled Geminin (mAG-
hGem), which indicates S/G2/M phase of cell cycle. A small gap in fluorescence 
change from red to green indicates a G1/S transition phase, already indicating an 
onset of S phase 12. Using these set of rules, the software differentiated between 
G1, G1/S and S/G2/M cells. Following this, the analysis was re-examined and 
errors were manually corrected and software was re-trained. After several iterations, 
the modified training set was used for the entire data set. 
 
 S4 
Click chemistry and visualization of single viral DNA dots 
HeLa-ATCC cells were grown on alcian-blue coated cover slips and infected with 
HAdV-C5-EdC (average bound particles per cell was 27) in the presence of FLV (15 
and 60 nM) at 37˚C for 1h. Unbound virus was washed away and infection 
continued for 2.5h. Cells were fixed with paraformaldehyde, and processed for 
Copper-catalyzed azide staining as described before 13. Virus capsids were 
visualized using the anti-hexon antibody Mab 9C12 (the antibody was developed by 
Laurence Fayadat and Wiebe Olijve, and obtained from Developmental Studies 
Hybridoma Bank developed under the auspices of the National Institute of Child 
Health and Human Development and maintained by the University of Iowa, 
Department of Biology, Iowa City, IA). Samples were imaged with Leica SP8 upright 
confocal microscope, and maximal projections were analyzed using Cell Profiler. 
DAPI staining was used to identify a nuclear mask, and the hexon channel (in 
overexposed mode) was used to segment the cell boundary. Capsid and DNA 
puncta over nucleus and within the cytoplasm were counted. 
 
Virus growth assay 
HCE cells were infected with HAdV-C2, D8 and D37 (moi of 0.008) at 37˚C for 2h. 
Cells were washed several times with PBS, and further incubated at 37˚C for 48h in 
growth medium containing 10% FBS. The cells were scraped and collected with 
medium, freeze thawed 3 three times and resultant virus titers were determined by 
infection of HeLa-ATCC cells with serial dilutions of the extracts and quantifying 
determining the number of hexon positive cells 
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